Lymphoid abnormalities in CD40 ligand transgenic mice suggest the need fortight regulation in gene therapy approaches to hyper immunoglobulin M (IgM) syndrome
Mg. Sacco et al., Lymphoid abnormalities in CD40 ligand transgenic mice suggest the need fortight regulation in gene therapy approaches to hyper immunoglobulin M (IgM) syndrome, CANC GENE T, 7(10), 2000, pp. 1299-1306
Mutations in the CD40 ligand (CD40L) are responsible for human hyper immuno
globulin M (IgM) syndrome. The absence of the interaction between CD40L, ex
pressed by T lymphocytes, and the CD40 receptor present on the surface of B
cells is responsible for the inability of B cells to carry out the isotype
switch from IgM to the other Ig classes. This leads to a fatal immunodefic
iency for which no cure exists. For these reasons, the CD40L gene is a good
candidate for gene therapy studies. To investigate the possible effects of
the expression of this tightly regulated gene in vivo, we produced transge
nic mice in which CD40L expression was deregulated. Widespread ectopic expr
ession appears to be lethal. Overexpression in mature T cells is compatible
with life, but in one-third of the cases, mice developed atypical lymphoid
proliferations which, occasionally, progressed into frank lymphomas. Even
though gene therapy is one of the most promising approaches to cure human h
yper IgM syndrome, these results suggest that when we modify very tightly r
egulated genes such as cytokines or other growth factors, particular care h
as to be taken to avoid excessive stimulation of the target cells.